Abstract
The 20th Hiroshima Cancer seminar focused upon breast cancer research and treatment particularly on the mechanism of tumorigenesis and drug resistance and development of novel therapeutics. Several molecules such as retinoblastoma and p16 were raised as key factors in tumorigenesis and invasiveness. Estrogen-related pathways seem to be closely involved in the process. For the tumor lacking hormone receptor and human epidermal growth factor 2, some other mechanisms could be responsible. It seems that MicroRNA 22 directing some putative targets such as SIRT1, Sp1 and CDK6 plays a crucial role in breast tumor growth and metastasis. In addition, ribophorin and the associated molecules might be engaged in breast cancer stemness. Obviously, these molecules provide potential for therapeutic targets. It was also discussed about new drug development such as anti-human epidermal growth factor 2 therapy, anti-angiogenesis, pro-tumor aspects of anti-cancer therapy and application of circulating markers for monitoring, imaging and health-care system. Furthermore, we discussed risk factors, prevention and screening to reduce invasive cancers as well. Throughout the conference, panelists and attendee indicated the importance of translational research and biomarker exploration in order to realize efficient and individualized therapy for breast cancer.
MeSH terms
-
Angiogenesis Inhibitors / pharmacology
-
Antineoplastic Agents / economics
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Biomarkers, Tumor / blood*
-
Biomarkers, Tumor / metabolism
-
Breast Neoplasms / blood
-
Breast Neoplasms / metabolism*
-
Breast Neoplasms / pathology
-
Breast Neoplasms / therapy*
-
Cell Transformation, Neoplastic* / drug effects
-
Cost-Benefit Analysis
-
Cyclin-Dependent Kinase 6 / metabolism
-
Cyclin-Dependent Kinase Inhibitor p16
-
Disease Progression
-
Drug Resistance, Neoplasm
-
Estrogens / metabolism
-
Female
-
Fluorodeoxyglucose F18
-
Hexosyltransferases
-
Humans
-
Insurance Coverage
-
International Cooperation
-
Membrane Proteins / metabolism
-
MicroRNAs / metabolism
-
Molecular Targeted Therapy* / methods
-
Neoplasm Proteins / drug effects
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / metabolism*
-
Positron-Emission Tomography / methods
-
Proteasome Endopeptidase Complex
-
Proteasome Inhibitors
-
Receptor, ErbB-2 / metabolism
-
Receptors, Immunologic / metabolism
-
Signal Transduction / drug effects
-
Sirtuin 1 / metabolism
-
Universities
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
CDKN2A protein, human
-
Cyclin-Dependent Kinase Inhibitor p16
-
Estrogens
-
MIRN22 microRNA, human
-
Membrane Proteins
-
MicroRNAs
-
Neoplasm Proteins
-
Proteasome Inhibitors
-
Receptors, Immunologic
-
ribophorin
-
trophoblastic beta 1-glycoprotein receptor, human
-
Fluorodeoxyglucose F18
-
Hexosyltransferases
-
RPN2 protein, human
-
ERBB2 protein, human
-
Receptor, ErbB-2
-
CDK6 protein, human
-
Cyclin-Dependent Kinase 6
-
Proteasome Endopeptidase Complex
-
SIRT1 protein, human
-
Sirtuin 1